MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- CIPLA (pharmaceuticals)
- CIPLA Financial Data
CIPLA Fact Sheet (CIPL)
Going LIVE Today at 5pm: The EV Gold Rush Special Event
Here is the latest financial fact sheet of CIPLA. For more details, see the CIPLA quarterly results and CIPLA share price and chart. For a sector overview, read our pharmaceuticals sector report.
CIPLA Price History
| 1 Day | % | -0.3 |
| No. of shares | m | 806.81 |
| 1 Week | % | 5.9 |
| 1 Month | % | -2.4 |
| 1 Year | % | 7.9 |
| 52 week H/L | Rs | 1,083.2/850.0 |
CIPLA Financials
| No. of Mths Year Ending |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
5-Yr Chart Click to enlarge
|
|---|
| CIPLA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 622 | 663 | 678 | 586 | 879 | |
| Low | Rs | 458 | 479 | 484 | 357 | 411 | |
| Sales per share (Unadj.) | Rs | 176.0 | 187.5 | 203.1 | 212.5 | 237.6 | |
| Earnings per share (Unadj.) | Rs | 13.0 | 17.6 | 18.7 | 19.2 | 29.8 | |
| Diluted earnings per share | Rs | 12.9 | 17.6 | 18.7 | 19.2 | 29.8 | |
| Cash flow per share (Unadj.) | Rs | 29.4 | 34.1 | 35.2 | 33.8 | 43.0 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | |
| Adj. dividends per share | Rs | 1.99 | 2.99 | 3.00 | 4.00 | 5.00 | |
| Avg Dividend yield | % | 0.4 | 0.5 | 0.5 | 0.8 | 0.8 | |
| Book value per share (Unadj.) | Rs | 155.1 | 175.9 | 185.6 | 194.9 | 226.7 | |
| Adj. book value per share | Rs | 154.7 | 175.5 | 185.4 | 194.7 | 226.6 | |
| Shares outstanding (eoy) | m | 804.51 | 805.12 | 805.70 | 806.24 | 806.46 | |
| Price / Sales ratio | x | 3.1 | 3.0 | 2.9 | 2.2 | 2.7 | |
| Avg P/E ratio | x | 41.7 | 32.4 | 31.0 | 24.6 | 21.6 | |
| P/CF ratio (eoy) | x | 18.4 | 16.8 | 16.5 | 14.0 | 15.0 | |
| Price / Book Value ratio | x | 3.5 | 3.2 | 3.1 | 2.4 | 2.8 | |
| Dividend payout | % | 15.4 | 17.0 | 16.0 | 20.8 | 16.8 | |
| Avg Mkt Cap | Rs m | 434,516 | 459,723 | 468,032 | 379,858 | 519,826 | |
| Total wages/salary | Rs m | 26,338 | 26,901 | 28,565 | 30,270 | 32,518 | |
| CIPLA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 141,583 | 150,922 | 163,624 | 171,320 | 191,596 | |
| Other income | Rs m | 2,287 | 3,577 | 4,766 | 3,694 | 2,698 | |
| Total revenues | Rs m | 143,870 | 154,498 | 168,390 | 175,014 | 194,294 | |
| Gross profit | Rs m | 24,758 | 27,489 | 30,973 | 31,808 | 42,487 | |
| Depreciation | Rs m | 13,229 | 13,228 | 13,263 | 11,747 | 10,677 | |
| Interest | Rs m | 1,594 | 1,142 | 1,684 | 1,974 | 1,607 | |
| Profit before tax | Rs m | 12,222 | 16,695 | 20,791 | 21,782 | 32,901 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 1,798 | 2,501 | 5,695 | 6,312 | 8,888 | |
| Profit after tax | Rs m | 10,424 | 14,194 | 15,096 | 15,470 | 24,013 | |
| Gross profit margin | % | 17.5 | 18.2 | 18.9 | 18.6 | 22.2 | |
| Effective tax rate | % | 14.7 | 15.0 | 27.4 | 29.0 | 27.0 | |
| Net profit margin | % | 7.4 | 9.4 | 9.2 | 9.0 | 12.5 | |
| CIPLA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 88,036 | 108,141 | 124,266 | 117,062 | 132,095 | |
| Current liabilities | Rs m | 33,889 | 38,322 | 37,715 | 43,931 | 45,916 | |
| Net working cap to sales | % | 38.2 | 46.3 | 52.9 | 42.7 | 45.0 | |
| Current ratio | x | 2.6 | 2.8 | 3.3 | 2.7 | 2.9 | |
| Inventory Days | Days | 45 | 49 | 72 | 50 | 68 | |
| Debtors Days | Days | 7 | 8 | 9 | 8 | 7 | |
| Net fixed assets | Rs m | 120,822 | 118,588 | 113,353 | 117,166 | 116,277 | |
| Share capital | Rs m | 1,609 | 1,610 | 1,611 | 1,613 | 1,613 | |
| "Free" reserves | Rs m | 123,207 | 140,019 | 147,941 | 155,487 | 181,232 | |
| Net worth | Rs m | 124,816 | 141,629 | 149,552 | 157,100 | 182,844 | |
| Long term debt | Rs m | 36,454 | 36,621 | 38,301 | 23,693 | 12,028 | |
| Total assets | Rs m | 208,858 | 226,729 | 237,619 | 234,228 | 248,372 | |
| Interest coverage | x | 8.7 | 15.6 | 13.3 | 12.0 | 21.5 | |
| Debt to equity ratio | x | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | |
| Sales to assets ratio | x | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | |
| Return on assets | % | 5.8 | 6.8 | 7.1 | 7.4 | 10.3 | |
| Return on equity | % | 8.4 | 10.0 | 10.1 | 9.8 | 13.1 | |
| Return on capital | % | 8.6 | 10.0 | 12.0 | 13.1 | 17.7 | |
| Exports to sales | % | 35.3 | 33.1 | 33.9 | 32.2 | 31.3 | |
| Imports to sales | % | 6.8 | 13.9 | 11.6 | 3.4 | 10.9 | |
| Exports (fob) | Rs m | 50,050 | 49,883 | 55,419 | 55,175 | 59,951 | |
| Imports (cif) | Rs m | 9,616 | 21,033 | 19,041 | 5,903 | 20,911 | |
| Fx inflow | Rs m | 51,066 | 51,691 | 57,410 | 56,036 | 68,051 | |
| Fx outflow | Rs m | 17,678 | 21,033 | 19,041 | 5,903 | 20,911 | |
| Net fx | Rs m | 33,388 | 30,658 | 38,368 | 50,133 | 47,140 | |
| CIPLA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 23,818 | 14,628 | 16,911 | 30,685 | 37,552 | |
| From Investments | Rs m | -13,102 | -8,540 | -16,687 | 1,040 | -23,872 | |
| From Financial Activity | Rs m | -13,257 | -3,855 | -3,487 | -29,488 | -13,299 | |
| Net Cashflow | Rs m | -2,478 | 2,431 | -3,451 | 2,340 | 509 | |
Share Holding
Shareholding as on Mar 2022
|
Company Information
|
|||||||||||||||||||||||||||||||||||||
| CHM: Y K Hamied | COMP SEC: Rajendra Chopra | YEAR OF INC: 1935 | BSE CODE: 500087 | FV (Rs): 2 | DIV YIELD (%): 0.5 |
More Pharmaceuticals Company Fact Sheets: SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN AUROBINDO PHARMA
Compare CIPLA With: SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN AUROBINDO PHARMA
Today's Market
Sensex Trades Higher Even as Metal Stocks Bleed; Tata Steel & JSW Steel Fall 12%(10:30 am)
Asian share markets are lower today as persistent worries about inflation and rising interest rates dogged the global economic outlook and fresh selling in technology stocks weighed on Chinese markets.
Views on news
Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)
Apr 13, 2022The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)
Sep 3, 2021These companies are likely to benefit the most from Covid-19 vaccines.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsMost Popular
2022's Best Performing Penny Stocks So Far... (Views On News)
Mar 2, 2022We are just two months into 2022 and several penny stocks that we track have already surged 5x.
5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)
Mar 16, 2022Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
Penny Stocks to Buy and Hold Beyond 2022 (Views On News)
Apr 6, 2022A step-by-step method to pick the best penny stocks for the long term.
6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)
Apr 13, 2022These penny stocks can become future multibaggers. Watch out for them.
Adani Power vs Tata Power: Which Power Stock is Better? (Views On News)
Feb 28, 2022Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - TEVA PHARMA COMPARISON
COMPARE CIPLA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.